{"id":"W4308977441","doi":"10.1093/neuonc/noac209.318","title":"CTNI-53. PNOC014: PHASE IB STUDY RESULTS OF DAY101(TOVORAFENIB) FOR CHILDREN WITH LOW-GRADE GLIOMAS (LGGS) AND OTHER RAS/RAF/MEK/ERK PATHWAY-ACTIVATED TUMORS","year":2022,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Dosing; Body surface area; MAPK/ERK pathway; Toxicity; MEK inhibitor; Adverse effect; Internal medicine; Oncology; Nuclear medicine; Kinase; Chemistry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003648875,0.0003898601,0.0009687417,0.0003583073,0.0002735563,0.00001597729,0.0001876301,0.000105468,0.0001082671],"category_scores_gemma":[0.0001863692,0.0003087228,0.0001316229,0.0005568807,0.0001791402,0.00006109487,0.0001717274,0.0003478559,0.000004198215],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000197748,"about_ca_system_score_gemma":0.0002910164,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002564418,"about_ca_topic_score_gemma":0.0001204915,"domain_scores_codex":[0.9972222,0.0003713229,0.0006524679,0.0008341076,0.0004201719,0.0004996779],"domain_scores_gemma":[0.997973,0.0005903396,0.0004664026,0.0006023758,0.0001123041,0.0002555659],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.02485877,0.04330728,0.1313459,0.0001005991,0.00163281,0.00300289,0.004935145,0.0001552681,0.7682074,0.0001755789,0.006427178,0.01585116],"study_design_scores_gemma":[0.2392272,0.1278947,0.09744479,0.0001010512,0.001847902,0.002338708,0.003575513,0.0002332149,0.4502124,0.00009657822,0.07611658,0.0009112818],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9931009,0.0001923985,0.00000601339,0.001480573,0.0002135363,0.003899368,0.000650894,0.00009992862,0.0003563676],"genre_scores_gemma":[0.9974671,0.00001007344,0.0001635935,0.0008690772,0.0001422981,0.001050738,0.0001701518,0.00009563982,0.00003135318],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.317995,"threshold_uncertainty_score":0.9999365,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02433929911267178,"score_gpt":0.310047491248283,"score_spread":0.2857081921356112,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}